BENGALURU, India and BRIDGEWATER, N.J., Oct. 1, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: BIOCON) ...

Last week, Biocon Biologics Ltd (“BBL”) announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) had issued positive opinions for Biocon’s two denosumab biosimilar candidates.

Biocon Pharma, a subsidiary of Biocon Ltd, has received approval from the USFDA for its generic Everolimus tablets to treat tuberous sclerosis complex. Available in 2 mg, 3 mg, and 5 mg, the drug is ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters, seeking to tap into a market that is ...

Biocon Pharma receives USFDA approval for generic Everolimus tablets, used to treat tuberous sclerosis complex (TSC).

Shares of Biocon rose 2% to Rs 364 on Friday, September 5, following the company’s announcement that the U.S. Food and Drug Administration (FDA) has concluded a routine current Good Manufacturing ...

HYDERABAD, Aug 11 (Reuters) - Indian biopharmaceutical company Biocon Ltd (BION.NS), opens new tab is planning to list its biosimilars business, a significant contributor to the company's total ...

MUMBAI (Reuters) - India's Biocon Ltd will retain milestone payments it received from Pfizer Inc as part of a deal that allowed the U.S. drugmaker to sell Biocon's insulin products globally, Biocon's ...

Shares of Steel Authority of India (SAIL) and Sammaan Capital are banned from F&O trading on 7 January 2026. Biocons subsidiary, Biocon Biologics will introduce three new oncology biosimilars at a US ...